A lot of people on social media are talking about the new study that was published in The Lancet last week. Let’s see what else has happened this summer.
Three things to take with you before we start
The summer brought several interesting findings, but most came from cross-sectional studies, small pilot studies or reviews rather than clinical trials.
Pain was one of the clearest themes, with several studies suggesting that symptom severity cannot be explained by BMI, lipedema stage or the amount of visible tissue alone.
Researchers are getting better at describing lipedema, but we still do not have a validated biomarker, a diagnostic scan or a medication proven to act directly on the disease.
This is therefore a research roundup, not a list of new facts that should immediately change treatment. Some findings may eventually become clinically useful, while others may disappear when they are tested in larger and better-designed studies. Interesting is not the same as proven, but it can still tell us where the field may be heading.
A large GLP-1 survey found a signal, not an answer
One of the largest studies this summer collected online responses from 2,719 people with lipedema, including current, former and never-users of GLP-1 or GLP-1/GIP medications. Current users reported less pain, swelling and functional limitation, as well as better physical and mental health, than people who had never used the medications. That is interesting, especially because more than half of the respondents were current users and tirzepatide was the most commonly reported medication. However, this was a cross-sectional, self-reported survey in which people were not randomly assigned to treatment, so it cannot tell us whether the medication caused the differences. It also cannot separate a possible direct effect on lipedema from weight loss, metabolic changes, selection effects or expectations, which makes this a reason to conduct proper trials rather than evidence that GLP-1 medications treat lipedema. Read the study.
Pain may involve more than the affected tissue
A study of 61 women with lipedema and 20 healthy controls found lower pressure-pain thresholds in the thigh, lower leg and forearm. The forearm is particularly interesting because it was used as a site outside the typically affected lower-limb tissue. The women with lipedema also had higher scores on a questionnaire used to identify features associated with central sensitization, while overall pain thresholds did not clearly follow lipedema stage. This suggests that altered pain processing in the nervous system may contribute to pain in at least some people with lipedema, but a cross-sectional study cannot establish how that change developed or whether it is a cause or consequence of long-term pain. For those living with lipedema, the important point is that pain may be real and severe even when its intensity does not match the amount of visible tissue. Read the study.
A second study pointed in the same direction
Another study compared 30 women with lipedema with 30 healthy controls and also found lower pressure-pain thresholds, including at sites outside the legs. Seventy per cent of the lipedema group scored above the study’s threshold for central sensitization, compared with 23 per cent of the controls. Anxiety, depressive symptoms and pain-related distress were also higher in the lipedema group and were associated with the sensitization scores. These findings do not mean that lipedema pain is psychological, nor do they show which factor came first; chronic pain itself can affect mood, sleep, vigilance and the way the nervous system responds. What they do support is a broader approach to pain care that considers both the affected tissue and the nervous system instead of assuming that tissue removal or volume reduction must explain every symptom. Read the study.
Pain did not follow BMI or stage
A separate observational study found that pain was common across BMI groups, clinical stages and body-shape classifications. Pain was more closely associated with touch sensitivity and the feeling of heavy legs than with BMI or the amount of fat measured in different body segments. Lean mass in the legs appeared relatively preserved, even though fat accumulation was greater in the lower body. This reinforces why BMI is a poor measure of how severely an individual is affected by lipedema, although neither heaviness nor touch sensitivity is specific enough to diagnose the condition. The practical message is that symptom burden and function need to be assessed directly rather than inferred from body size or stage alone. Read the study.
Quality of life was comparable to advanced cancer in several areas
A Swedish study compared 104 women with lipedema with 42 healthy women and, as an exploratory comparison, 44 women with advanced cancer. The lipedema group reported lower health-related quality of life than the healthy controls in every area that was measured. In several areas, including physical functioning and pain, their scores were comparable to those reported by the women with advanced cancer, while their rating of general health was even lower. This does not mean that lipedema and advanced cancer are medically equivalent, because the study compared questionnaire scores rather than disease severity or prognosis. It does, however, document a level of daily burden that health systems should not dismiss as a cosmetic concern. Read the study.
Sexual health is also part of the disease burden
Researchers compared 50 sexually active women with lipedema with 50 women of similar age and BMI without lipedema. Seventy-six per cent of the lipedema group scored below the questionnaire threshold used to indicate sexual dysfunction, compared with 36 per cent of the controls. Lower sexual-function scores were related to pain, depressive symptoms, poorer perceived health and reduced lower-limb function. Because the study captured one point in time, it cannot show that lipedema directly caused these difficulties or explain the role of relationships, medication, hormones and other health conditions. Still, it makes an often-overlooked part of quality of life visible and supports including sexual health in respectful, whole-person care when the patient wants to discuss it. Read the study.
Many lymphatic scans were normal
A systematic review brought together seven studies that included 311 women with lipedema who had undergone lymphoscintigraphy. Around 61 per cent had scans described as normal, while some of the remaining women showed winding or collateral lymphatic vessels and other changes. Clearer signs associated with lymphatic failure, such as dermal backflow or secondary lymphedema, were much less common. The authors interpreted the overall pattern as more consistent with lymphatic overload than with established lymphatic insufficiency, but the studies used different scanning methods and could not be combined in a formal meta-analysis. A normal lymphoscintigram therefore does not rule out lipedema, and an abnormal result still needs to be interpreted together with symptoms and a clinical examination. Read the study.
Ultrasound may help assess the arms, but it is not a diagnostic answer
A study compared ultrasound measurements at six points on the arms of 51 women with lipedema and 51 women matched for age and BMI. The subcutaneous tissue was thicker at every measured site in the lipedema group, and the middle of the upper arm performed best when the researchers tested a possible cut-off value. That measurement identified many of the women with lipedema, but its specificity was only about 52 per cent, meaning that many people without lipedema could also be classified as positive. The results suggest that standardized ultrasound could add information when arm involvement is suspected, especially when combined with a clinical examination. They do not establish a stand-alone scan or a universal thickness threshold that can confirm upper-body lipedema. Read the study.
One small study found a possible vascular clue
Researchers measured several blood markers related to inflammation, adipose tissue and blood-vessel growth in 23 premenopausal women with lipedema and 23 comparison participants. Most of the markers did not differ between the groups, which is as important to report as the one result that did. The lipedema group had lower levels of endostatin, a protein involved in limiting the formation of new blood vessels. This could fit with the growing interest in altered small blood vessels and vascular regulation in lipedema, but the study was small and measured the participants only once. Endostatin is therefore a possible research lead, not a diagnostic blood test or proof of how lipedema develops. Read the study.
Systemic inflammation looked similar to obesity
A retrospective study examined routine blood-based inflammation measures in 78 women with lipedema, 76 women with obesity but not lipedema and 75 normal-weight controls. Some markers, including C-reactive protein and the erythrocyte sedimentation rate, were higher in both the lipedema and obesity groups than in the normal-weight group. The lipedema and obesity groups, however, did not differ clearly from one another, and several composite immune-cell measures were similar across all three groups. This suggests that the low-grade systemic inflammation detected by routine blood tests may be strongly influenced by adiposity rather than forming a unique lipedema signature. It does not rule out inflammation inside lipedema tissue, but it warns us not to describe every raised inflammatory marker as disease-specific. Read the study.
A small metabolomics study found a different fasting pattern
Another study examined fasting blood samples from 24 premenopausal women with lipedema and 21 BMI-matched controls. The women with lipedema had lower fasting insulin, smaller waist measurements, lower levels of several molecules involved in glucose breakdown and higher signals from ketone bodies. When the researchers combined these measures, the two groups showed partial separation rather than two completely distinct metabolic profiles. This is an intriguing clue that fat distribution and fasting metabolism in lipedema may differ from what BMI alone would predict, but the sample was far too small to establish a diagnostic metabolic signature. Larger studies will need to test whether the pattern is reproducible and whether diet, activity, body-fat distribution or other factors explain part of it. Read the study.
Coexisting obesity still carried metabolic risk
A study of 70 people with both lipedema and obesity and 70 people with obesity alone compared fasting glucose, cholesterol and several calculated markers of cardiovascular and metabolic risk. Most measures were similar between the groups, although LDL cholesterol was lower in the lipedema group. The result suggests that lipedema did not add a clearly different systemic risk profile once obesity was already present. More importantly, it challenges the idea that having lipedema automatically protects a person from the metabolic consequences associated with obesity. Individual screening and care should therefore be based on actual health measures, not on the assumption that everyone with lipedema is either metabolically healthy or metabolically unwell. Read the study.
Lipedema appeared to add burden beyond obesity alone
The LipObes study compared 30 people who had both lipedema and obesity with 29 people who had obesity without lipedema. Despite broadly similar body-composition measures, the lipedema group reported more pain and showed lower pain thresholds in both the arms and legs. They also had poorer quadriceps strength, mobility, exercise capacity and quality of life, together with greater body-image concerns and more difficulty around eating. The study was small and cross-sectional, so it cannot tell us how these differences developed or which interventions would improve them. It nevertheless supports the view that lipedema can add a distinct functional and symptomatic burden that is not captured by an obesity diagnosis alone. Read the study.
Diet quality was linked with pain and inflammation
A study of 86 women with lipedema found that a more pro-inflammatory dietary score was associated with greater pain and higher C-reactive protein, while stronger adherence to a Mediterranean-style diet was associated with better physical quality of life. The proportion of energy reported from ultra-processed foods also increased across lipedema stages. However, BMI, body-fat percentage and inflammatory markers increased across the same stages, making it difficult to separate diet from body composition, symptoms and other lifestyle factors. Food intake was self-reported and the study was cross-sectional, so it cannot show that ultra-processed food causes lipedema progression or that a Mediterranean diet treats the disease. The useful conclusion is more modest: diet quality may be connected to symptom burden and deserves testing in controlled studies without turning one dietary pattern into a promise or a moral judgment. Read the study.
Physical therapy remains useful, but the evidence is still thin
An integrative review examined conservative physical-therapy approaches including compression, exercise, manual techniques, complete decongestive therapy and treatments using physical energy. Across the available literature, these approaches showed potential to reduce pain, support function and help manage swelling. The problem is that the studies were limited and often differed in their methods, participants and outcomes, making firm comparisons difficult. This means that a person can experience genuine relief from a therapy even though researchers still cannot say precisely who benefits most, by how much or for how long. For now, conservative care is best understood as individualized symptom and function management while better clinical trials are developed. Read the review.
A heat-treatment pilot changed circumference, but not pain or tissue thickness
A small controlled pilot tested ten sessions of high-intensity heat diathermy in nine women and a sham treatment in another nine. The treated group showed a reduction in the circumference of the left knee that was still detectable five weeks later. The researchers did not find clear improvements in ultrasound-measured tissue thickness, pressure-pain thresholds or reported pain. With only 18 participants and a change that was not consistent across all measures, the study cannot show that the treatment reduced lipedema fat. It is an early signal worth investigating, but not strong evidence for adding diathermy to routine lipedema care. Read the study.
Hormones are being turned into testable research questions
One paper proposed viewing lipedema as a vulnerability in hormone-sensitive connective and adipose tissue rather than as an isolated problem of enlarged fat cells. It organized existing ideas into four interacting areas: sensitivity during hormonal transitions, metabolic and behavioural influences, gynecological and endocrine conditions, and vulnerability within the tissue itself. The authors also proposed that local steroid metabolism and the balance between different estrogen receptors could help connect these areas. This is a research framework, not a study demonstrating that these mechanisms cause lipedema, and much of the biology is extrapolated from research outside lipedema. Its value is in producing questions that can be tested, not in justifying hormone tests, supplements or hormone-altering treatments today. Read the paper.
Endometriosis offered a possible model for studying pain
A narrative review compared pain biology in lipedema with the much more developed research field around endometriosis. The authors proposed that immune cells, sensory nerves, local hormone activity and inflammatory signalling might interact in both conditions and help amplify pain. In endometriosis, several parts of this model have direct experimental support, while the corresponding evidence in lipedema remains incomplete or hypothetical. The idea could help explain why pain sometimes changes with hormonal phases or appears more severe than visible tissue changes would suggest. It is a biologically plausible research direction, but it does not yet prove a shared disease mechanism or provide a new treatment recommendation. Read the review.
A proposed hormone treatment had no direct clinical evidence
Another review asked whether gestrinone, a hormone-altering medication sometimes proposed for lipedema, had actually been tested in people with the condition. The authors found no clinical trials, observational studies, case series or even individual case reports directly evaluating it for lipedema. Existing arguments for its use were based on theoretical hormonal mechanisms rather than patient evidence. That does not prove the drug could never have an effect, but it means benefits and harms for lipedema are currently unknown. This is an important reminder that a plausible biological story is not enough to support an off-label treatment, especially when hormones are being altered. Read the review.
Better research may begin with everyone measuring the same things
The Lipedema Foundation and an international group of clinicians, researchers and statisticians developed a common form for collecting lipedema research data. It contains 682 possible data elements, divided into core, recommended, supplemental and exploratory categories. That may sound less exciting than a new treatment, but inconsistent definitions and measurements are a major reason why lipedema studies are difficult to compare. The form is not a diagnostic standard and is not intended to tell clinicians how to treat an individual patient. If widely adopted and refined, it could make future studies easier to combine and improve the search for reliable subgroups, biomarkers and treatment outcomes. Read the paper.
Artificial intelligence reproduced the most familiar lipedema image
Researchers asked an image-generating AI system to create 300 images representing the five anatomical lipedema types. The system generated convincing examples of Types I, II and III, but failed to produce the arm-predominant Type IV and calf-limited Type V patterns. Instead, all images requested for those two types were classified by clinicians as the more familiar Type III pattern, leaving overall accuracy at 60 per cent. This suggests that generative AI can reproduce the dominant visual stereotype of lipedema while erasing less common presentations. AI-generated medical images should therefore not be treated as neutral educational material without expert review and much more representative training data. Read the study.
The bigger picture
The most encouraging part of this summer is not that researchers have found one explanation for lipedema. They have not. It is that the questions are becoming broader and more precise: how pain is processed, how lipedema differs from obesity, what imaging can and cannot show, how the disease affects everyday life, and which biological ideas are ready to be tested rather than simply repeated.
At the same time, the limitations are still visible. Many studies are small, cross-sectional or based on self-reported information, and several papers propose frameworks rather than presenting new experimental evidence. The field is moving, but it will move more reliably if interesting findings are replicated, negative results are taken seriously and treatment claims are held to a higher standard than plausible stories.
That is how LipedemaScience will continue to follow the research with curiosity when something is new, with caution when the evidence is early, and with a clear distinction between what a study found and what we still do not know.